US LNG exports surge but will buyers in China turn up?
NEWTON, Mass. - Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a $90 million market cap biotech company that has seen its stock surge over 23% in the past week, announced Tuesday it has entered into a collaboration agreement with JCR Pharmaceuticals to develop an oligomer-targeted Enhanced Brain Delivery therapy for Alzheimer’s disease. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 8.02, though it faces profitability challenges.
The partnership aims to combine Acumen’s amyloid beta oligomer-selective antibody expertise with JCR’s blood-brain barrier penetrating technology, known as J-Brain Cargo. The collaboration follows more than a year of feasibility work between the two companies. InvestingPro subscribers can access 12 additional key insights about Acumen’s financial health and market performance through the comprehensive Pro Research Report, one of 1,400+ detailed company analyses available on the platform.
"We are thrilled to enter into this collaboration pairing Acumen’s AβO-targeted antibody expertise with JCR’s validated proprietary BBB-penetrating technology," said Daniel O’Connell, Chief Executive Officer of Acumen.
The blood-brain barrier presents challenges for delivering therapeutics, particularly larger molecules like biologics, into the brain. JCR’s technology uses receptor-mediated transcytosis to efficiently deliver drugs to target tissues, including the central nervous system.
Under the agreement terms, JCR will receive an upfront payment and could receive an additional option payment if Acumen exercises its exclusive right to develop up to two development candidates. JCR will also be eligible for future development, commercialization and sales milestone payments, plus single-digit percentage royalties on product sales.
The companies expect preclinical candidate data in early 2026, at which point Acumen has an exclusive option to advance development candidates.
Acumen’s lead program, sabirnetug, is currently being evaluated in the Phase 2 ALTITUDE-AD clinical trial for early Alzheimer’s disease. The company completed enrollment of 542 patients in March 2025 and plans to share topline results in late 2026. While the company reported a net loss of $116.25 million in the last twelve months, InvestingPro data shows it maintains a healthy balance sheet with more cash than debt, crucial for supporting its ongoing clinical development programs.
This information is based on a press release statement from Acumen Pharmaceuticals.
In other recent news, Acumen Pharmaceuticals reported its first-quarter 2025 financial results, showing a net loss of $28.8 million. Despite the financial loss, the company maintains a strong cash position with $197.9 million in cash and marketable securities, expected to support operations into early 2027. The company has also completed enrollment for its ALTITUDE AD phase two study ahead of schedule, emphasizing its focus on Alzheimer’s drug development. Citi initiated coverage on Acumen Pharmaceuticals with a buy rating, setting a price target of $4.00, and noted the company’s unique approach to Alzheimer’s treatment. The firm highlighted promising Phase 1 data for Acumen’s lead drug, sabirnetug, which targets toxic amyloid beta oligomers. Citi also expressed optimism about the development of a subcutaneous formulation of sabirnetug, despite acknowledging the high-risk nature of the Alzheimer’s treatment market. Acumen Pharmaceuticals is continuing to advance its Alzheimer’s treatment pipeline, with top-line results for the ALTITUDE AD study anticipated in late 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.